Table 2.
Summary of cases form the University of Florida Neuromedicine Human Brain and Tissue Bank used in this study
| Case | Clinical diagnosis | Primary pathological diagnosis | Secondary pathological diagnosis | Amyloid score (Thal) | Braak | CERAD | Gender | Age | PMI (hrs) |
|---|---|---|---|---|---|---|---|---|---|
| Control 1 | Normal | AD low | 1 | II | none | M | 88 | 4 | |
| Control 2 | Normal | PART | 0 | II | none | F | 72 | 4 | |
| Control 3 | Normal | No significant pathological findings | 0 | 0 | none | F | 55 | 12 | |
| Control 4 | Progressive Myoclonic Epilepsy (Unverricht-Lundborg variant: EPM1)* | No significant pathological findings | 0 | 0 | 0 | M | 51 | 31 | |
| FTLD-1 | FTLD | FTLD-TDP43 | 1 | 0 | none | F | 67 | 30 | |
| MSA-1 | MSA-C | MSA | 0 | 0 | none | F | 67 | 4 | |
| MSA-2 | MSA-P | MSA | AD low | 1 | I | none | F | 60 | 6 |
| MSA-3 | MSA-P | MSA | PART | 0 | II | none | M | 77 | 18 |
| MSA-4 | MSA-C | MSA | AD low; CAA | 2 | I | sparse | M | 71 | 4 |
| MSA-5 | MSA-C | MSA | AD intermediate | 2 | III | sparse | M | 59 | 4 |
| MSA-6 | MSA-P/C | MSA | PART, CAA | 0 | I | none | F | 66 | 22 |
| MSA-7 | MSA-P | MSA | 0 | 0 | none | F | 66 | 14 | |
| LBD-1 | DLB | LBD diffuse neocortical | AD intermediate; CAA | 3 | IV | moderate | M | 67 | 13 |
| LBD-2 | DLB | LBD diffuse neocortical | AD intermediate; CAA; ARTAG | 3 | III | sparse | F | 67 | 4 |
| LBD-3 | AD | LBD diffuse neocortical | AD intermediate; CAA | 3 | IV | frequent | F | 81 | 15 |
| LBD-4 | AD | LBD diffuse neocortical | AD high; CAA | 3 | V | frequent | F | 74 | 8 |
| LBD-5 | AD | LBD diffuse neocortical | AD high; CAA | 3 | VI | frequent | M | 80 | 21 |
| AD/ALB-1 | AD | LBD limbic-transitional | AD intermediate; CAA | 2 | V | moderate | F | 83 | 9 |
| AD/ALB-2 | AD | LBD amygdala | AD high; CAA | 3 | VI | frequent | M | 64 | 3 |
| AD/ALB-3 | AD | LBD amygdala | AD high; CAA | 3 | VI | frequent | F | 67 | 8 |
Listed are the clinical and pathological diagnoses, the sex, age at death, amyloid score (Thal), Braak stage and CERAD ratings. AD Alzheimer’s disease, AD/ALB AD with amygdala restricted Lewy bodies, ARTAG aging related tau astrogliopathy, CAA cerebral amyloid angiopathy, DLB dementia with Lewy body, FTLD frontotemporal lobar degeneration, LATE limbic-predominant age related TDP-43 encephalopathy, LBD Lewy body dementia, MSA-C multiple system atrophy with predominant cerebellar ataxia, MSA-P multiple system atrophy with predominant Parkinsonism, PART primary age-related tauopathy, PMI postmortem interval. * CTSB mutation